Multicellular spheroids in ovarian cancer metastases: Biology and pathology

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 143-148

  Shield, Kristy ^a,b   Ackland, M Leigh ^a   Ahmed, Nuzhat ^c,d   Rice, Gregory E ^b  

^a DEAKIN UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chemo resistance; Chemotherapy; Epithelial ovarian cancer; Metastasis; Spheroids

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; PACLITAXEL; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER MODEL; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CARCINOGENESIS; CELL ANCHORAGE; CELL FUNCTION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOLAYER CULTURE; MULTICELLULAR SPHEROID; NONHUMAN; OVARY CANCER; OVARY METASTASIS; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE; VASCULARIZATION;

FEMALE; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; SPHEROIDS, CELLULAR;

EID: 62749197305     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.032     Document Type: Review

References (59)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 1 (2007) 43-66
2. AIHW. Ovarian Cancer in Australia: an Overview (2006), Australian Institute of Health and Welfare & National Breast Cancer Center, Canberra
3. Naora H., and Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev., Cancer 5 5 (2005) 355-366
4. Allen H.J., Porter C., Gamarra M., Piver M.S., and Johnson E.A. Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions. Exp. Cell Biol. 55 4 (1987) 194-208
5. Burleson K.M., Boente M.P., Pambuccian S.E., and Skubitz A.P. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J. Transl. Med. 4 (2006) 6
6. L'Esperance S., Bachvarova M., Tetu B., Mes-Masson A.M., and Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 9 1 (2008) 99
7. Shield K., Riley C., Quinn M.A., Rice G.E., Ackland M.L., and Ahmed N. alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J. Carcinog. 6 1 (2007) 11
8. Zietarska M., Maugard C.M., Filali-Mouhim A., Alam-Fahmy M., Tonin P.N., Provencher D.M., et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol. Carcinog. 46 10 (2007) 872-885
9. Auersperg N., Woo M.M., and Gilks C.B. The origin of ovarian carcinomas: a developmental view. Gynecol. Oncol. 110 3 (2008) 452-454
10. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?. Gynecol. Oncol. 72 3 (1999) 437-442
11. Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., and Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 23 1 (2004) 41-44
12. Auersperg N., Wong A.S., Choi K.C., Kang S.K., and Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22 2 (2001) 255-288
13. Naora H. The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev. Mol. Med. 9 13 (2007) 1-12
14. Serov S.F., Scully R.E., and Sobin L.H. Histological Typing of Ovarian Tumours (1973), World Health Organisation, Geneva
15. Cheng W., Liu J., Yoshida H., Rosen D., and Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat. Med. 11 5 (2005) 531-537
16. Colombo N., Van Gorp T., Parma G., Amant F., Gatta G., Sessa C., et al. Ovarian cancer. Crit. Rev., Oncol./Hematol. 60 2 (2006) 159-179
17. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 351 24 (2004) 2519-2529
18. Shepherd J.H. Revised FIGO staging for gynaecological cancer. Br. J. Obstet. Gynaecol. 96 8 (1989) 889-892
19. Ahmed N., Thompson E.W., and Quinn M.A. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J. Cell. Physiol. 213 3 (2007) 581-588
20. Burleson K.M., Hansen L.K., and Skubitz A.P. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis 21 8 (2004) 685-697
21. Hagemann T., Robinson S.C., Thompson R.G., Charles K., Kulbe H., and Balkwill F.R. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol. Cancer Ther. 6 7 (2007) 1993-2002
22. Kantak S.S., and Kramer R.H. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J. Biol. Chem. 273 27 (1998) 16953-16961
23. Burleson K.M., Casey R.C., Skubitz K.M., Pambuccian S.E., Oegema Jr. T.R., and Skubitz A.P. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 93 1 (2004) 170-181
24. Puiffe M.L., Le Page C., Filali-Mouhim A., Zietarska M., Ouellet V., Tonin P.N., et al. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9 10 (2007) 820-829
25. Waleh N.S., Gallo J., Grant T.D., Murphy B.J., Kramer R.H., and Sutherland R.M. Selective down-regulation of integrin receptors in spheroids of squamous cell carcinoma. Cancer Res. 54 3 (1994) 838-843
26. Suzuki S.T. Structural and functional diversity of cadherin superfamily: are new members of cadherin superfamily involved in signal transduction pathway?. J. Cell. Biochem. 61 4 (1996) 531-542
27. Aberle H., Schwartz H., and Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J. Cell. Biochem. 61 4 (1996) 514-523
28. Kostetskii I., Li J., Xiong Y., Zhou R., Ferrari V.A., Patel V.V., et al. Induced deletion of the N-cadherin gene in the heart leads to dissolution of the intercalated disc structure. Circ. Res. 96 3 (2005) 346-354
29. Morris A.P., Tawil A., Berkova Z., Wible L., Smith C.W., and Cunningham S.A. Junctional Adhesion Molecules (JAMs) are differentially expressed in fibroblasts and co-localize with ZO-1 to adherens-like junctions. Cell Adhes. Commun. 13 4 (2006) 233-247
30. Cowin P., Rowlands T.M., and Hatsell S.J. Cadherins and catenins in breast cancer. Curr. Opin. Cell Biol. 17 5 (2005) 499-508
31. Patel I.S., Madan P., Getsios S., Bertrand M.A., and MacCalman C.D. Cadherin switching in ovarian cancer progression. Int. J. Cancer 106 2 (2003) 172-177
32. Zhu Y., and Sundfeldt K. Tight junction formation in epithelial ovarian adenocarcinoma. Acta Obstet. Gynecol. Scand. 86 8 (2007) 1011-1019
33. Sundfeldt K. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol. Cell. Endocrinol. 202 1-2 (2003) 89-96
34. Sarrio D., Moreno-Bueno G., Sanchez-Estevez C., Banon-Rodriguez I., Hernandez-Cortes G., Hardisson D., et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum. Pathol. 37 8 (2006) 1042-1049
35. Veatch A.L., Carson L.F., and Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int. J. Cancer 58 3 (1994) 393-399
36. Kim Y.J., Sauer C., Testa K., Wahl J.K., Svoboda R.A., Johnson K.R., et al. Modulating the strength of cadherin adhesion: evidence for a novel adhesion complex. J. Cell. Sci. 118 Pt 17 (2005) 3883-3894
37. Ivascu A., and Kubbies M. Diversity of cell-mediated adhesions in breast cancer spheroids. Int. J. Oncol. 31 6 (2007) 1403-1413
38. Islam S., Kim J.B., Trendel J., Wheelock M.J., and Johnson K.R. Vimentin expression in human squamous carcinoma cells: relationship with phenotypic changes and cadherin-based cell adhesion. J. Cell. Biochem. 78 1 (2000) 141-150
39. Gumbiner B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 84 3 (1996) 345-357
40. Santini M.T., Rainaldi G., and Indovina P.L. Multicellular tumour spheroids in radiation biology. Int. J. Radiat. Biol. 75 7 (1999) 787-799
41. Mueller-Klieser W. Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am. J. Physiol. 273 4 Pt 1 (1997) C1109-C1123
42. Sutherland R.M., McCredie J.A., and Inch W.R. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J. Natl. Cancer Inst. 46 1 (1971) 113-120
43. Sutherland R.M., and Durand R.E. Radiation response of multicell spheroids-an in vitro tumour model. Curr. Top Radiat. Res. Q. 11 1 (1976) 87-139
44. Kobayashi H., Man S., Graham C.H., Kapitain S.J., Teicher B.A., and Kerbel R.S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. U. S. A. 90 8 (1993) 3294-3298
45. Sutherland R.M., Inch W.R., McCredie J.A., and Kruuv J. A multi-component radiation survival curve using an in vitro tumour model. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 18 5 (1970) 491-495
46. Makhija S., Taylor D.D., Gibb R.K., and Gercel-Taylor C. Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int. J. Oncol. 14 3 (1999) 515-521
47. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68 11 (2008) 4311-4320
48. Bapat S.A., Mali A.M., Koppikar C.B., and Kurrey N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65 8 (2005) 3025-3029
49. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65 13 (2005) 5506-5511
50. Winter III W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 25 24 (2007) 3621-3627
51. Eisenkop S.M., Spirtos N.M., and Lin W.C. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol. Oncol. 103 1 (2006) 329-335
52. Lin H., and Changchien C.C. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches. Taiwan J. Obstet. Gynecol. 46 4 (2007) 379-388
53. Guppy A.E., Nathan P.D., and Rustin G.J. Epithelial ovarian cancer: a review of current management. Clin. Oncol. (R. Coll. Radiol.) 17 6 (2005) 399-411
54. Piccart M.J., Lamb H., and Vermorken J.B. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann. Oncol. 12 9 (2001) 1195-1203
55. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 54 (1985) 665-697
56. Nishio S., Sugiyama T., Shouji T., Yoshizaki A., Kitagawa R., Ushijima K., et al. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecol. Oncol. 106 2 (2007) 342-347
57. Martin L., and Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J. Clin. Oncol. 25 20 (2007) 2894-2901
58. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol (in press).
59. de Bree E., Theodoropoulos P.A., Rosing H., Michalakis J., Romanos J., Beijnen J.H., et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat. Rev. 32 6 (2006) 471-482